A Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in Patients with PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2024
This article has no abstract
Epistemonikos ID: 1b14ffbba865ac9fa8893d9fdf1da974fb6a1047
First added on: Mar 21, 2025